Recorded Presentation from the NCCN Pharmacy Updates: Assessment and Management of CAR T-Cell Related Toxicities
CAR T-cell products have the ability to completely change the treatment paradigm for hematologic malignancies. These therapies are associated with life-threatening toxicities that require rapid intervention. Newly published consensus statements to better define and grade these toxicities should be incorporated into clinical practice.
- Management of Immunotherapy-Related Toxicities
- Recorded Webcast
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours